Lowering Elevated LDL-C Remains a Significant Unmet Need

Cardiovascular disease (CVD), which results in heart attacks, strokes and other cardiovascular events, represents the number one cause of death and disability globally. According to American Heart Association estimates, in the U.S.:

  • CVD accounts for 1 in 3 deaths
  • Someone has a heart attack approximately every 40 seconds
  • CVD expenses, including stroke, in the U.S. were $317 billion in 2012-2013; including the cost of healthcare services, medications and lost productivity.(1)

Elevated LDL-C is a significant risk factor for cardiovascular disease. The CDC (Centers for Disease Control) through NHANES (National Health & Nutrition Examination Survey) estimates that 81 million(2) U.S. adults have elevated levels of LDL-C (also known as hypercholesterolemia). In the U.S., increasing attention has been placed on aggressive LDL-C lowering. This has led to the combination of statins with other treatments to reach LDL-C goals.

Current Treatment Options May Not Be Adequate for All Patients

Current lipid-lowering therapies are effective at lowering LDL-C, with well-documented benefits. However, some patients can have difficulty accessing them, and not all patients can tolerate them or reach their LDL-C target on maximally-tolerated dosing.

Patients with atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH) who require additional LDL-C lowering on top of maximally-tolerated therapy represent a high-risk patient population with an unmet medical need.

  • Approximately 40 million(2) US adults with elevated LDL-C levels are taking a statin
  • Approximately 12 to 13 million ASCVD and/or HeFH patients with elevated LDL-C levels are currently unable to achieve their LDL-C target despite taking maximally-tolerated statin therapy(3)


(1) Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, Das SR, de Ferranti S, Després J-P, Fullerton HJ, Howard VJ, Huffman MD, Isasi CR, Jiménez MC, Judd SE, Kissela BM, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Magid DJ, McGuire DK, Mohler ER III, Moy CS, Muntner P, Mussolino ME, Nasir K, Neumar RW, Nichol G, Palaniappan L, Pandey DK, Reeves MJ, Rodriguez CJ, Rosamond W, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Woo D, Yeh RW, Turner MB; on behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2016 update: a report from the American Heart Association. Circulation. 2016;133:e188.

(2) Glickman M. 2018 Investor and Analyst Day. The Opportunity, the Providers, and the Patients. July 2018. http://investor.esperion.com/static-files/978fb8ef-869c-4ee2-b54c-6ae7ec2bc59a

(3) Esperion analysis, NHANES 2018.